関連する実験動画

Updated: Sep 10, 2025

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

IDOR-1104-0086,ネズミの抗発作効果を持つ新しいKv7チャネルアクティベーター

Melanie Kessler¹, Andreas Mühlemann¹, Malgorzata Anna Mis¹

¹Idorsia Pharmaceuticals Ltd, Department of Drug Discovery, CNS-Pharmacology Division, Allschwil, Switzerland.

Neuropharmacology

|August 27, 2025

まとめ

新しい薬剤候補であるIDOR-1104-0086は,Kv7チャネルを活性化することによって,集中発作および一般的な発作を効果的に軽減します. この有望な抗発作薬はレチガビンよりも効力があり,臨床前モデルではよく耐えます.

科学分野:

神経科学
薬理学について
分子生物学

背景:

電圧ゲートされたカリウム (Kv7) チャンネルは,神経の興奮性を調節するために不可欠です.
Kv7チャネルを活性化することでの治療策が提供されます
レチガビンのような既存のKV7チャネルオープナーには限界があります.

研究の目的:

小分子IDOR-1104-0086の抗発作能力の特徴を明らかにする.
Kv7イソフォームのレチガビンとの効能と選択性を比較する.
様々なネズミの発作モデルでの有効性を評価する.

主な方法:

IDOR-1104- 0086を in vitro 発現型スクリーニングで特定した.
そのメカニズムはKV7チャネルの活性化でした
in vivo研究では, amigdala-kindling, 6 Hz,最大電気ショックの値,および欠席のようなのモデルが使用されました.
電気生理学 (全細胞パッチクランプ) でチャネル活動を評価した.

主要な成果:

IDOR-1104- 0086は,脳特有のKv7. 2/ 3とKv7. 3/ 5の経路においてレチガビンより高い効能を示した.
心臓Kv7. 1チャネルでは無効であり,周辺の安全性を示した.
この化合物は,用量に依存して,発作の焦点および一般的発作を減少させ,欠席のような発作を悪化させた.
このメカニズムと一致するKv7. 2/ 3のアクティベーションをインビオ有効濃度でシフトさせた.

結論:

IDOR-1104- 0086は抗発作特性を有する強力なKv7. 2/ 3チャネル活性化剤です.
臨床前モデルでは,集中発作および一般的発作を効果的に減少させる.
この化合物は特定のタイプの,特に薬剤耐性の治療に有望な候補である.

キーワード:

エピレプシー KCNQ Kv7.2/3 についてカリウムチャンネルネズミのモデル押収する

さらに関連する動画

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

関連する概念動画

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...